117 results on '"Moppett, J"'
Search Results
2. Correlation between microsatellite discrepancy scores and transplant outcome after haemopoietic SCT for pediatric ALL
3. High thrombotic risk of T-lymphoblastic lymphoma treated with intensive asparaginase containing ALL regimes; retrospective, observational data from a single centre: 229
4. Global tests of blood clotting during asparaginase treatment for acute lymphoblastic leukaemia. Preliminary results of the GlobALL study: 107
5. Improved survival in matched unrelated donor transplant for childhood ALL since the introduction of high-resolution matching at HLA class I and II
6. G244(P) “Blessing in Disguise”: Noonan Syndrome with JMML
7. COMMUNICATING HYDROCEPHALUS IN CHILDREN WITH MALIGNANT INFANTILE OSTEOPETROSIS AND ATP6I (TCIRG1) MUTATION UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: PH-AB127
8. ADENOVIRUS TYPE A31 AS A CAUSE OF AN UNEXPECTED PERSISTENT INCREASED INCIDENCE OF ADENOVIRAEMIA ON A STEM CELL TRANSPLANTATION UNIT: PH-P491
9. ‘Stroke-like syndrome’ caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial
10. Discrepancy analysis of microsatellite loci as a proxy for ancestral differentiation between donors and recipients: correlation between high scores and poorer overall survival in children undergoing matched unrelated donor transplantation for ALL: O175
11. The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. (Review)
12. Hyperglycaemia during induction therapy for acute lymphoblastic leukaemia (ALL) is associated with increased risk of infection
13. A case of ITP thatʼll make you go blue in the face
14. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation
15. Impact of immune modulation with anti-T cell antibodies on outcomes after unrelated donor transplantation for acute lymphoblastic leukaemia in children and adolescents: O400
16. Stenotrophomonas maltophilia bacteraemia in 40 haematology patients: risk factors, therapy and outcome
17. High peripheral blood progenitor cell counts enable autologous backup before stem cell transplantation for malignant infantile osteopetrosis
18. Allogeneic bone marrow transplantation in 355 patients for acute lymphoblastic leukaemia in children: a 20-year single-centre experience
19. Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin
20. Expression of prolactin receptor mRNA in oestrogen receptor positive breast cancers pre- and post-tamoxifen therapy
21. Neonatal neuroblastoma
22. Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia
23. Comparison of clinical significance of MRD as determined by IgH genescanning or allele specific probing in childhood ALL
24. Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting tests
25. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia
26. ‘Stroke-like syndrome’ caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial
27. Stenotrophomonas maltophilia bacteraemia in 40 haematology patients: risk factors, therapy and outcome
28. Comparison of EMLA and lidocaine iontophoresis for cannulation analgesia.
29. Second malignancies in children: the usual suspects?
30. Pregnancy, tacrolimus, and renal transplantation: survival of a 358-g baby.
31. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement
32. Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia
33. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
34. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
35. Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction.
36. Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.
37. Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3 + T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts.
38. Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL.
39. Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation.
40. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
41. Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
42. Metabolomics: A biomarker to improve the assessment of central nervous system positive acute lymphoblastic leukaemia?
43. High-throughput sequencing of peripheral blood for minimal residual disease monitoring in childhood precursor B-cell acute lymphoblastic leukemia: A prospective feasibility study.
44. Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols.
45. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials.
46. Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia.
47. The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
48. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
49. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
50. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.